Literature DB >> 22462694

A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources.

Hossein Haji Ali Afzali1, Jonathan Karnon, Jodi Gray.   

Abstract

Depression is the most common mental health disorder and is recognized as a chronic disease characterized by multiple acute episodes/relapses. Although modelling techniques play an increasingly important role in the economic evaluation of depression interventions, comparatively little attention has been paid to issues around modelling studies with a focus on potential biases. This, however, is important as different modelling approaches, variations in model structure and input parameters may produce different results, and hence different policy decisions. This paper presents a critical review of literature on recently published model-based cost-utility studies of depression. Taking depression as an illustrative example, through this review, we discuss a number of specific issues in relation to the use of decision-analytic models including the type of modelling techniques, structure of models and data sources. The potential benefits and limitations of each modelling technique are discussed and factors influencing the choice of modelling techniques are addressed. This review found that model-based studies of depression used various simulation techniques. We note that a discrete-event simulation may be the preferred technique for the economic evaluation of depression due to the greater flexibility with respect to handling time compared with other individual-based modelling techniques. Considering prognosis and management of depression, the structure of the reviewed models are discussed. We argue that a few reviewed models did not include some important structural aspects such as the possibility of relapse or the increased risk of suicide in patients with depression. Finally, the appropriateness of data sources used to estimate input parameters with a focus on transition probabilities is addressed. We argue that the above issues can potentially bias results and reduce the comparability of economic evaluations.

Entities:  

Mesh:

Year:  2012        PMID: 22462694     DOI: 10.2165/11590500-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  89 in total

1.  Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.

Authors:  Jonathan Karnon
Journal:  Health Econ       Date:  2003-10       Impact factor: 3.046

2.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

3.  A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.

Authors:  S A Montgomery; J G Rasmussen; P Tanghøj
Journal:  Int Clin Psychopharmacol       Date:  1993       Impact factor: 1.659

4.  The effect of episodes on recurrence in affective disorder: a case register study.

Authors:  L V Kessing; P K Andersen
Journal:  J Affect Disord       Date:  1999-06       Impact factor: 4.839

5.  A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.

Authors:  Patrick W Sullivan; Robert Valuck; Joseph Saseen; Holly M MacFall
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Prediction of the three-year course of recurrent depression in primary care patients: different risk factors for different outcomes.

Authors:  Henk Jan Conradi; Peter de Jonge; Johan Ormel
Journal:  J Affect Disord       Date:  2007-06-14       Impact factor: 4.839

7.  Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.

Authors:  Agnes Benedict; Jorge Arellano; Erwin De Cock; Jessamy Baird
Journal:  J Affect Disord       Date:  2010-01       Impact factor: 4.839

8.  Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment With Bupropion Sustained Release: A Study in Patients With Major Depression.

Authors:  David L. Dunner; W Jacqueline Kwong; Trisha L. Houser; Nathalie E. Richard; Rafe M. J. Donahue; Zeba M. Khan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-02

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

10.  Cost utility analysis of maintenance treatment for recurrent depression.

Authors:  M S Kamlet; N Paul; J Greenhouse; D Kupfer; E Frank; M Wade
Journal:  Control Clin Trials       Date:  1995-02
View more
  6 in total

1.  A proposed model for economic evaluations of major depressive disorder.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Eur J Health Econ       Date:  2011-06-02

Review 2.  Model Structuring for Economic Evaluations of New Health Technologies.

Authors:  Hossein Haji Ali Afzali; Laura Bojke; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

3.  Research aimed at improving both mood and weight (RAINBOW) in primary care: A type 1 hybrid design randomized controlled trial.

Authors:  Jun Ma; Veronica Yank; Nan Lv; Jeremy D Goldhaber-Fiebert; Megan A Lewis; M Kaye Kramer; Mark B Snowden; Lisa G Rosas; Lan Xiao; Andrea C Blonstein
Journal:  Contemp Clin Trials       Date:  2015-06-19       Impact factor: 2.226

4.  Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community.

Authors:  Jonathan Tosh; Ben Kearns; Alan Brennan; Glenys Parry; Thomas Ricketts; David Saxon; Alexis Kilgarriff-Foster; Anna Thake; Eleni Chambers; Rebecca Hutten
Journal:  BMC Health Serv Res       Date:  2013-04-26       Impact factor: 2.655

Review 5.  Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review.

Authors:  Spyros Kolovos; Judith E Bosmans; Heleen Riper; Karine Chevreul; Veerle M H Coupé; Maurits W van Tulder
Journal:  Pharmacoecon Open       Date:  2017-09

Review 6.  A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process.

Authors:  Fang Li; Frederike Jörg; Xinyu Li; Talitha Feenstra
Journal:  Pharmacoeconomics       Date:  2022-09-14       Impact factor: 4.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.